Patents by Inventor Enzo Paoletti
Enzo Paoletti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5762938Abstract: What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.Type: GrantFiled: August 21, 1996Date of Patent: June 9, 1998Assignee: Virogenetics CorporationInventors: Enzo Paoletti, Marion E. Perkus, Jill Taylor, James Tartaglia, Elizabeth K. Norton, Michel Riviere, Charles de Taisne, Keith J. Limbach, Gerard P. Johnson, Steven E. Pincus, William I. Cox, Jean-Christophe Francis Audonnet, Russell Robert Gettig
-
Patent number: 5759552Abstract: What is described is a recombinant poxvirus, such as vaccinia virus or fowlpox virus, containing foreign DNA from Marek's disease virus. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine.Type: GrantFiled: March 7, 1994Date of Patent: June 2, 1998Assignee: Virogenetics CorporationInventors: Enzo Paoletti, Jill Taylor, James Tartaglia, Louis Ross
-
Patent number: 5759841Abstract: What is described is a recombinant poxvirus, such as vaccinia virus or canarypox virus, containing foreign DNA from Morbillivirus. In one embodiment, the foreign DNA is expressed in a host by the production of a measles virus glycoprotein. In another embodiment, the foreign DNA is expressed in a host by the production of at least two measles virus glycoproteins. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine. By the present invention, cross-protection of dogs against canine distemper is obtained by inoculating the dog with the recombinant poxvirus.Type: GrantFiled: June 7, 1995Date of Patent: June 2, 1998Assignee: Virogenetics CorporationInventors: Enzo Paoletti, Jill Taylor
-
Patent number: 5759553Abstract: What is described is a recombinant poxvirus, such as vaccinia virus or fowlpox virus, containing foreign DNA from Marek's disease virus. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine.Type: GrantFiled: June 7, 1995Date of Patent: June 2, 1998Assignee: Virogenetics CorporationInventors: Enzo Paoletti, Jill Taylor, James Tartaglia, Louis Ross
-
Patent number: 5756103Abstract: What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.Type: GrantFiled: June 1, 1995Date of Patent: May 26, 1998Assignee: Virogenetics CorporationInventors: Enzo Paoletti, Marion E. Perkus, Jill Taylor, James Tartaglia, Elizabeth K. Norton, Michel Riviere, Charles de Taisne, Keith J. Limbach, Gerard P. Johnson, Steven E. Pincus, William I. Cox, Jean-Christophe Francis Audonnet, Russell Robert Gettig
-
Patent number: 5756101Abstract: What is described is a recombinant poxvirus, such as vaccinia virus, containing foreign DNA from Plasmodium Merozoite Surface Antigen 1. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine.Type: GrantFiled: January 7, 1994Date of Patent: May 26, 1998Assignees: Pasteur Merieux serums et Vaccins, University of HawaiiInventors: Enzo Paoletti, Charles de Taisne, Sandra Chang, George Hui, Wasim Siddiqui
-
Patent number: 5756102Abstract: Attenuated recombinant viruses containing DNA coding for a canine distemper virus antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: canine distemper virus fusion protein and canine distemper virus hemagglutinin glycoprotein. The recombinant viruses and gene products therefrom are useful for eliciting protection against canine distemper virus.Type: GrantFiled: April 6, 1994Date of Patent: May 26, 1998Assignee: Virogenetics CorporationInventors: Enzo Paoletti, James Tartaglia, Jill Taylor
-
Patent number: 5744140Abstract: What is described is a recombinant poxvirus, such as vaccinia virus, fowlpox virus and canarypox virus, containing foreign DNA from flavivirus, such as Japanese encephalitis virus, yellow fever virus and Dengue virus. In a preferred embodiment, the recombinant poxvirus generates an extracellular particle containing flavivirus E and M proteins capable of inducing neutralizing antibodies, hemagglutination-inhibiting antibodies and protective immunity against flavivirus infection. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine.Type: GrantFiled: April 7, 1994Date of Patent: April 28, 1998Assignee: Virgenetics CorporationInventors: Enzo Paoletti, Steven Elliot Pincus
-
Patent number: 5744141Abstract: What is described is a recombinant poxvirus, such as vaccinia virus, fowlpox virus and canarypox virus, containing foreign DNA from flavivirus, such as Japanese encephalitis virus, yellow fever virus and Dengue virus. In a preferred embodiment, the recombinant poxvirus generates an extracellular particle containing flavivirus E and M proteins capable of inducing neutralizing antibodies, hemagglutination-inhibiting antibodies and protective immunity against flavivirus infection. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine.Type: GrantFiled: June 7, 1995Date of Patent: April 28, 1998Assignee: Virogenetics CorporationInventors: Enzo Paoletti, Steven Elliot Pincus
-
Patent number: 5688920Abstract: Disclosed and claimed are nucleotides for genes encoding the canine herpesvirus (CHV) gB, gC and gD homologues. These genes encode polypeptides of 879, 459 and 345 amino acids, respectively, which are also disclosed and claimed. The genes are useful as DNA probes or, for preparing PCR primers. The polypeptides are useful in antigenic, immunological or vaccine compositions. The nucleotides can be expressed in any suitable vector system, allowing for production of the polypeptides. Additionally, the vector system containing any or any combination of the nucleotides can be employed in an antigenic, immunological or vaccine composition, such as a poxvirus vector system, e.g., a CHV-vaccinia or avipox virus recombinant, as can the products from expression, i.e., the gB, gC and gD glycoproteins. Antibodies elicited by the glycoproteins or from expression of the vector containing the nucleotide(s) are also useful. Methods for making and using the composition are also disclosed and claimed.Type: GrantFiled: March 29, 1995Date of Patent: November 18, 1997Assignee: Virogenetics CorporationInventors: Enzo Paoletti, Keith J. Limbach
-
Patent number: 5658572Abstract: What is described is a recombinant poxvirus, such as fowlpox virus, containing foreign DNA from infectious bursal disease virus. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine.Type: GrantFiled: February 28, 1994Date of Patent: August 19, 1997Assignee: Virogenetics CorporationInventors: Enzo Paoletti, Jill Taylor
-
Patent number: 5641490Abstract: What is described is a recombinant poxvirus, such as fowlpox virus, containing foreign DNA from infectious bursal disease virus. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine.Type: GrantFiled: September 7, 1994Date of Patent: June 24, 1997Assignee: Virogenetics CorporationInventors: Enzo Paoletti, Jill Taylor, Russell Gettig
-
Patent number: 5583028Abstract: Disclosed and claimed are DNA constructs encoding HSV glycoproteins. The constructs are recombinant vaccinia virus, and host cells infected by the recombinant vaccinia virus are also disclosed and claimed.Type: GrantFiled: September 13, 1994Date of Patent: December 10, 1996Assignee: Health Research IncorporatedInventors: Enzo Paoletti, Dennis Panicali
-
Patent number: 5529780Abstract: Disclosed and claimed are nucleotides for genes encoding the canine herpesvirus (CHV) gB, gC and gD homologues. These genes encode polypeptides of 879, 459 and 345 amino acids, respectively, which are also disclosed. The nucleotides can be expressed in any suitable vector system, allowing for production of the polypeptides. Additionally, the vector system containing any or any combination of the nucleotides can be employed in an antigenic, immunological or vaccine composition, such as a poxvirus vector system, e.g., a CHV-vaccinia or avipox virus recombinant, as can the products from expression, i.e., the gB, gC and gD glycoproteins. Antibodies elicited by the glycoproteins or from expression of the vector containing the nucleotide are also useful. Methods for making and using the composition are also disclosed and claimed.Type: GrantFiled: March 30, 1994Date of Patent: June 25, 1996Assignee: Virogenetics CorporationInventors: Enzo Paoletti, Keith J. Limbach
-
Patent number: 5514375Abstract: What is described is a recombinant poxvirus, such as vaccinia virus, fowlpox virus and canarypox virus, containing foreign DNA from flavivirus, such as Japanese encephalitis virus, yellow fever virus and Dengue virus. In a preferred embodiment, the recombinant poxvirus generates an extracellular particle containing flavivirus E and M proteins capable of inducing neutralizing antibodies, hemagglutination-inhibiting antibodies and protective immunity against flavivirus infection. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine.Type: GrantFiled: June 13, 1991Date of Patent: May 7, 1996Assignee: Virogenetics CorporationInventors: Enzo Paoletti, Steven E. Pincus
-
Patent number: 5505941Abstract: The present invention provides a method for inducing an immunological response in a mammal or avian host to a pathogen by inoculating the mammal or avian host with a synthetic recombinant avipox virus modified by the presence, in a non-essential region of the avipox genome, of DNA from any source which codes for and expresses an antigen of the pathogen. The present invention further provides a synthetic recombinant avipox virus modified by the insertion therein of DNA from any source, and particularly from a non-avipox source, into a non-essential region of the avipox genome.Type: GrantFiled: July 22, 1992Date of Patent: April 9, 1996Assignee: Health Research, Inc.Inventor: Enzo Paoletti
-
Patent number: 5503834Abstract: What is described is a recombinant poxvirus, such as vaccinia virus or canarypox virus, containing foreign DNA from Morbillivirus. In one embodiment, the foreign DNA is expressed in a host by the production of a measles virus glycoprotein. In another embodiment, the foreign DNA is expressed in a host by the production of at least two measles virus glycoproteins. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine. By the present invention, cross-protection of dogs against canine distemper is obtained by inoculating the dog with the recombinant poxvirus.Type: GrantFiled: June 8, 1993Date of Patent: April 2, 1996Assignee: Virogenetics CorporationInventors: Enzo Paoletti, Jill Taylor
-
Patent number: 5494807Abstract: What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.Type: GrantFiled: August 12, 1993Date of Patent: February 27, 1996Assignee: Virogenetics CorporationInventors: Enzo Paoletti, Marion E. Perkus, Jill Taylor, James Tartaglia, Elizabeth K. Norton, Michel Riviere, Charles de Taisne, Keith J. Limbach, Gerard P. Johnson, Steven E. Pincus, William I. Cox, Jean-Christophe F. Audonnet, Russell R. Gettig
-
Patent number: 5482713Abstract: What is described is a recombinant poxvirus, such as vaccinia virus, fowlpox virus and canarypox virus, containing foreign DNA from herpesvirus. In one embodiment, the foreign DNA is expressed in a host by the production of a herpesvirus glycoprotein. In another embodiment, the foreign DNA is expressed in a host by the production of at least two, particularly two or three, herpesvirus glycoproteins. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine. By the present invention, the barrier of maternal immunity in a newborn offspring can be overcome or avoided.Type: GrantFiled: September 21, 1993Date of Patent: January 9, 1996Assignee: Health Research IncorporatedInventor: Enzo Paoletti
-
Patent number: 5453364Abstract: What is described is a modified recombinant virus for expressing a gene product in a host. The modified recombinant virus has host range genes deleted therefrom so that the virus has restricted replication in the host. The modified recombinant virus also contains DNA which codes for and expresses the gene product in the host even with restricted replication of the virus in the host. The modified recombinant virus is used in a method for expressing a gene product in a host or in a cell cultured in vitro, and in a vaccine for inducing an immunological response in a host inoculated with the vaccine. What is also described is a selection system for the cloning and expression of open reading frames in poxviruses, particularly vaccinia virus. The selection system is based on a conditional lethal mutant (host range) of poxviruses.Type: GrantFiled: August 5, 1993Date of Patent: September 26, 1995Assignee: Health Research IncorporatedInventor: Enzo Paoletti